Search results
Results From The WOW.Com Content Network
Lorcaserin, marketed under the brand name Belviq, [4] [5] was a weight-loss drug developed by Arena Pharmaceuticals. It reduces appetite by activating serotonin receptor the 5-HT 2C receptor in the hypothalamus , a region of the brain which is known to control appetite. [ 6 ]
Lorcaserin (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. [ 11 ] Cannabinoid receptor antagonists were developed to treat obesity because researchers noticed that cannabinoid agonists (such as THC , the main pharmacologically active component ...
Still used as veterinary drug and as a human antihelminthic in many markets; listed on the WHO List of Essential Medicines. In humans, it was used to treat melanoma before it was withdrawn for agranulocytosis. [29] [30] [31] Levomethadyl acetate: 2003 US Cardiac arrhythmias and cardiac arrest. [2] Lorcaserin (Belviq) 2020 US Increased risk of ...
Pholcodine can trigger allergic reactions and is common in cough syrups
Lorcaserin is the only agent that has completed phase III clinical trials, and achieved US Food and Drug Administration (FDA) approval. However it was later withdrawn from the market in February 2020 due to a higher risk of malignancy in a randomized trial of lorcaserin. [39] Previously approved agents were subsequently removed from the US ...
Lorcaserin used to be approved by the Food and Drug Administration for use in the treatment of obesity before being withdrawn due to cancer risk. [72] Recombinant human leptin is very effective in those with obesity due to congenital complete leptin deficiency via decreasing energy intake and possibly increases energy expenditure. This ...
Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant which has been discontinued in many countries. It works as a serotonin–norepinephrine reuptake inhibitor (SNRI) similar to certain antidepressants.
People seeking information about lorcaserin (or any other subject) should find factual information, good and bad. I'm well aware that lorcaserin is a touchy subject for investors. If the drug is approved, it's likely to be a gigantic money-maker just as fenfluramine was. Arena estimates that sales will net $1 billion per year.